Sector
PharmaceuticalsOpen
₹3.17Prev. Close
₹3.02Turnover(Lac.)
₹0Day's High
₹3.17Day's Low
₹3.1752 Week's High
₹3.1752 Week's Low
₹2.28Book Value
₹-6.3Face Value
₹10Mkt Cap (₹ Cr.)
1.35P/E
0EPS
0Divi. Yield
014 Aug 2024
12:00 AM
AGM
Announcement Date: 14 Aug, 2024
29 Mar 2025
12:00 AM
EGM
25 Mar 2025
12:00 AM
Board Meeting
Agenda : Audited Result
14 Aug 2024
12:00 AM
BookCloser
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 4.27 | 4.27 | 4.27 | 4.27 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -6.68 | -6.58 | -6.41 | -6.33 |
Net Worth | -2.41 | -2.31 | -2.14 | -2.06 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 |
yoy growth (%) | 0 | 0 | 0 | 0 |
Raw materials | 0 | 0 | 0 | 0 |
As % of sales | 0 | 0 | 0 | 0 |
Employee costs | -0.02 | -0.01 | -0.01 | -0.01 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | -0.06 | -0.02 | -0.02 | -0.02 |
Depreciation | 0 | 0 | 0 | 0 |
Tax paid | 0 | 0 | 0 | 0 |
Working capital | 0.08 | -0.06 | -0.04 | 0 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 0 | 0 | 0 | 0 |
Op profit growth | 129.2 | -8.19 | 3.76 | 26.28 |
EBIT growth | 196.15 | -16.65 | 3.01 | 79.79 |
Net profit growth | 23.59 | -1.66 | 13.34 | 33.05 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,788.9 | 133.07 | 4,19,223.8 | 1,181.05 | 0.77 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,917.85 | 75.76 | 1,57,045.9 | 594 | 0.51 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,533.55 | 26.52 | 1,23,411.97 | 1,438.15 | 0.85 | 4,134.87 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,334.35 | 60.21 | 1,09,829.07 | 485 | 0.86 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,545.05 | 54.95 | 1,06,261.66 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Independent Director
Harsh Prabhakar
Independent Director
Poonam Sharma
Managing Director & CFO
Prashant Nathmal Bajaj
Non Executive Director
Hitesh Bajoria
Non Executive Director
Tushar Pandit Awate
Non Executive Director
Urmila Hansraj Sharma
Non Executive Director
Nishant Nathmal Bajaj
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Raymed Labs Ltd
Summary
Raymed Labs Ltd was established in the year 1994 as a pharmaceutical company with emphasis on injectables with state of the art manufacturing facilities on Dehradun Road, Saharanpur, UP. The Company embarked on a new and exciting phase of its growth journey. As a widely operational pharmaceutical company, it proved excellence in the competitive ophthalmology industry with its robust marketing infrastructure across the geographies.Raymed created an integrated multi-technology capability to manufacture all types of formulations with innovative and advanced technologies focusing into Preservative free Ophthalmic dosage specially for Conjunctivitis and Glaucoma Patient care, Various other formulations have been converted from suspension to solution which helps in the effective absorption, penetration and better patience compliance.Highly skilled technicians operate multiple manufacturing facilities with the world class technology, having ultramodern equipment and machineries for manufacturing formulations in wide range of dosage forms. All are facilities are certified with WHO-GMP, ISO 9001:2008 and various International accreditations like ANVISA-Brazil, NAFDAC-Nigeria, FDB-Ghana, PMPB-Malawi amongst others. Expanding with time the Company has a comprehensive range of over 80 products, Raymed is a trademark owner of ophthalmic solution (eye drops), antioxidant capsules and tablets.
Read More
What is the Raymed Labs Ltd share price today?
The Raymed Labs Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is ₹3.17 today.
What is the Market Cap of Raymed Labs Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Raymed Labs Ltd is ₹1.35 Cr. as of 24 Mar ‘25
What is the PE and PB ratio of Raymed Labs Ltd?
The PE and PB ratios of Raymed Labs Ltd is 0 and -0.50 as of 24 Mar ‘25
What is the 52 Week High and Low of Raymed Labs Ltd?
The 52-week high/low is the highest and lowest price at which a Raymed Labs Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Raymed Labs Ltd is ₹2.28 and ₹3.17 as of 24 Mar ‘25
What is the CAGR of Raymed Labs Ltd?
Raymed Labs Ltd's CAGR for 5 Years at 26.99%, 3 Years at 26.12%, 1 Year at 45.41%, 6 Month at 15.27%, 3 Month at 10.07% and 1 Month at 4.97%.
What is the shareholding pattern of Raymed Labs Ltd?
The shareholding pattern of Raymed Labs Ltd is as follows:
Promoters - 28.36 %
Institutions - 0.96 %
Public - 70.68 %
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
